721401-53-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Thiophenecarboxamide, 5-chloro-N-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]is used as a potential therapeutic agent for the treatment of various diseases. Its unique chemical structure allows it to interact with specific biological targets, such as enzymes or receptors, which can lead to the modulation of cellular processes and the amelioration of disease symptoms.
Used in Chemical Synthesis:
2-ThiophenecarboxaMide, 5-chloro-N-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-Morpholinyl)phenyl]aMino]propyl]can be used as a building block or intermediate in the synthesis of more complex molecules with specific applications. Its diverse functional groups make it a versatile starting material for the development of new drugs, agrochemicals, or other specialty chemicals.
Used in Material Science:
The unique structural features of 2-Thiophenecarboxamide, 5-chloro-N-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]may also find applications in the development of new materials with specific properties. For example, it could be used to create novel polymers, coatings, or other materials with tailored characteristics for various industrial applications.
Used in Research and Development:
Due to its complex structure and potential for various applications, 2-ThiophenecarboxaMide, 5-chloro-N-[(2R)-2-hydroxy-3-[[4-(3-oxo-4-Morpholinyl)phenyl]aMino]propyl]- can be a valuable tool in research and development. It can be used to study the effects of different functional groups and structural features on the properties and activities of molecules, which can provide valuable insights for the design of new compounds with specific applications.

Upstream product

• 721401-52-1 (S)-N-(3-bromo-2-hydroxypropyl)-5-chlorothiophene-2-carboxamide 
• 438056-69-0 4-(4-aminophenyl)morpholin-3-one 
• 348626-26-6 5-chloro-N-(oxiran-2-ylmethyl)thiophene-2-carboxamide 
• 71-36-3 butan-1-ol 
• 42518-98-9 5-chlorothiophene-2-carbonyl chloride 
• 1384257-81-1 N-[(2S)-3-chloro-2-hydroxypropyl]-5-chlorothiophene-2-carboxamide 
• 366789-02-8 Rivaroxaban 
• 446292-04-2 4-(4-nitrophenyl)-3-morpholinone 
• 29518-11-4 4-phenylmorpholin-3-one 
• 62-53-3 aniline 
• 122-98-5 2-Anilinoethanol 
• 22353-82-8 5-chlorothiophene-2-carboxamide 
• 35475-03-7 methyl 5-chloro-2-thiophenecarboxylate 
• 1403383-56-1 (S)-4-[4-[(3-amino-2-hydroxypropyl)amino]phenyl]-3-morpholinone 

Downstream Products

• 366789-02-8 Rivaroxaban 
• 913565-18-1 5-Chloro-N-({(5S)-2-imino-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)-thiophene-2-carboxamide 

Relevant academic research and scientific papers

Hydrolytic degradation study of rivaroxaban: Degradant products identification by LC-MS isolation by Prep-HPLC and characterization by HRMS, NMR and FT-IR

Present work illustrates the stress degradation behaviour of rivaroxaban under hydrolytic, oxidative, thermal and photolytic conditions as per ICH guidelines. Under thermal and photolytic conditions drug had a fair stability where as in other stress conditions degradation products were observed. Initial identification of the degradation products was performed by hyphenated mass spectrometry coupled to ultra-performance liquid chromatography (UPLC-MS) and mass directed auto purification (MDAP) was used for isolation. Various 1D and 2D nuclear magnetic resonance (NMR) were performed to characterize the degradation products which were assisted by FT-IR and HRMS data. Two novel degradant products were observed in hydrolytic conditions, isolated and characterized by spectroscopic techniques as (R)-2-(2-((4-((3-(5-chlorothiophene-2-carboxamido)-2-hydroxypropyl)amino)phenyl)amino)ethoxy)acetic acid (DP-2) (m.w. of 427.90 g/mol and m.f. C18H22N3O5SCl), and 5-chlorothiophene-2-carboxylic acid (DP-3) (m.w. 161.95 g/mol and m.f. C5H3O2SCl). Additionally, two more degradation products were observed in basic and acidic conditions, viz. (R)-5-chloro-N-(2-hydroxy-3-((4-(3-oxomorpholino)phenyl)amino)propyl)thiophene-2-carboxamide (DP-1) (m.w. 409.09 g/mol and m.f. C18H20N3O4SCl) and (S)-2-(2-((4-(5-((5-chlorothiophene-2-carboxamido)methyl)-2-oxooxazolidin-3-yl)phenyl)amino)ethoxy)acetic acid (DP-4) (m.w. 453.08g /mol and m.f. C19H20N3O6SCl) are already reported.

Rivaroxaban thiophene carboxylate impurity reference substance and preparation method thereof

The invention discloses a synthesis method of a rivaroxaban thiophene carboxylate impurity. The full name of the impurity is: 1-amino-3 ((4-(3-oxomorpholino) phenyl) amino) prop-2-yl 5-chlorothiophene-2-carboxylic acid ethyl ester hydrochloride. The invention also discloses a preparation method of the rivaroxaban thiophene carboxylate impurity. The preparation method comprises the following steps:dissolving rivaroxaban oxazolidine in an organic solvent, carrying out ring opening under the action of an acidic solution to obtain a rivaroxaban thiophene carboxylate impurity crude product, and recrystallizing with the organic solvent to obtain the high-purity rivaroxaban thiophene carboxylate impurity reference substance. The rivaroxaban thiophene carboxylate impurity is simple in preparationprocess and high in purity, and a qualified rivaroxaban thiophene carboxylate impurity reference substance can be provided for quality control of rivaroxaban.

Method for preparing rivaroxaban intermediate and method for preparing rivaroxaban from rivaroxaban intermediate

The invention provides a method for preparing a rivaroxaban intermediate shown as a formula (VI) and a method for preparing rivaroxaban. The preparation method of the intermediate has the advantages of simple steps, easily controlled conditions, good selectivity, high yield, few impurities and the like, and green synthesis of rivaroxaban can be realized.

The preparation method of the [...] (by machine translation)

The invention provides a method for preparing [...], using 4 - (4 - aminophenyl) - 3 - morpholone and 5 - chloro - N - (2 - ethylene oxide-based methyl) - 2 - thiophene carboxamide reaction to obtain 5 - [...] - 2 - {(R)- 2 - hydroxy - 3 - [4 - (3 - oxo - 4 - morpholinyl) phenyl amino] - propyl} amide, then adding N, N' - carbonyl di-imidazole, 4 - dimethylamino pyridine, begins to stir, heating reaction to obtain the - 5 - chloro - N - (( (5 S) - 2 - oxo - 3 - (4 - (3 - oxo-morpholine - 4 - yl) phenyl) - 1, 3 - Oxacillin - 5 - yl) methyl) thiophene - 2 - carboxamide. The technique of the invention route after the condition is optimized, mild reaction, high yield. (by machine translation)

A oxazolidinone compounds of preparation method

The invention discloses a method for preparing an oxazolidinone compound. The method comprises the following steps of carrying out ammonolysis reaction on a racemic or optically active 3-chloro-2-hydroxypropyl aniline compound (2) as a starting material and ammonia in a proper solvent and under alkaline condition to obtain a 3-amino-2-hydroxypropyl aniline compound (3); carrying out acylation reaction on the compound (3) to obtain 3-acylamino-2-hydroxypropyl aniline compound (4); and carrying out cyclization reaction on the compound (4) and a corresponding acylating reagent to obtain the racemic or optically active oxazolidinone compound (II) as shown in the description, wherein R1 represents morpholinyl or 3-oxo-4-morpholinyl; R2 represents H or F; and R3 represents C1-12 alkyl, 5-chloro-thiophen-2-yl, thiophen-2-yl or 4,5-dichloro-2-yl; and the compound is a racemate and (S)- or (R)- optical isomers.

A method for preparing the advantage cuts down Sha Ban

The invention discloses a preparation method of rivaroxaban, belonging to the field of chemical synthesis of medicine. The preparation method of rivaroxaban comprises the following steps: reacting 5-chlorothiophene-2-carboxylic acid-[(s)-2,3-dyhydroxy propyl]-amide with iodine under the catalytic action of triphenylphosphine and imidazole to produce 5-chlorothiophene-2-carboxylic acid-[(s)-3-iodo-2-hydroxy propyl]-amide; then reacting 5-chlorothiophene-2-carboxylic acid-[(s)-3-iodo-2-hydroxy propyl]-amide with 4-(4-aminophenyl)-3-morpholinone to produce 5-chlorothiophene-2-carboxylic acid{(R)-2-hydroxy-3-[4-(3-oxomorpholine-4-yl) phenyl amino]-propyl} amide; and finally introducing CO2 to react to produce rivaroxaban. The preparation method provided by the invention has the advantages that expensive and poisonous raw materials are not used, the production cost is low, the production safety is high, the environment pollution is hardly caused. Therefore, the preparation method is suitable for industrial production.

N-epoxy propyl-N-acyl aniline compounds, process for their preparation and use

The present invention discloses a class of N-epoxypropyl-N-acylaniline compounds represented by a formula (I), and further discloses a preparation method of the N-epoxypropyl-N-acylaniline compounds, and applications of the N-epoxypropyl-N-acylaniline compounds in preparation of oxazolidinone treating drugs including but being not limited to linezolid and rivaroxaban racemate or optical isomers, wherein R1 represents morpholinyl or 3-O-4-morpholinyl, R2 represents H or F, R3 represents C1-12 alkyl, thien-2-yl or 5-chlorothiophen-2-yl, and the compounds are racemates, (S)-optical isomers, or (R)-optical isomers.

PROCESS FOR THE PREPARATION OF RIVAROXABAN

The present invention provides processes for the preparation of rivaroxaban. The present invention also provides processes for the preparation of a rivaroxaban intermediate.

PROCESS FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF

The present invention provides processes for the preparation of rivaroxaban and its intermediates.

METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to methods for the preparation of a compound having the formula (X). Individual reaction steps as welt as intermediates are additionally claimed.